An observational study in Chronic Hepatitis b and Non-Alcoholic Fatty Liver Disease, sponsored by Beijing Friendship Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-28.
Sponsored by Beijing Friendship Hospital · Observational
Totals of 400 chronic hepatitis B or non-alcoholic fatty liver disease (NAFLD) patients with or without cirrhosis will be enrolled. Patients' clinical characteristics, including alanine aminotransferase, aspartic aminotransferase, total bilirubin, direct bilirubin, indirect bilirubin, triglyceride and total cholesterol, hepatitis B surface antigen, steatosis, and liver stiffness measurement will be collected. The consistence of liver fibrosis and steatosis assessment between Hepatus and FibroScan will be evaluated in this study.
2,709 studies on the registry are indexed under Hepatitis A; 142 are open to participants now.
This study's planned enrollment of 400 is above the median of 250 across 687 observational studies indexed under Hepatitis A.
Browse Hepatitis A studies →Beijing Friendship Hospital is the lead sponsor of 216 studies on the registry; 95 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with or without cirrhosis diagnose as chronic hepatitis B or non-alcoholic fatty liver disease.
Exclusion Criteria:
Consistency of liver stiffness and steatosis results in the same location between Hepatus in continuous measurement mode and FibroScan in single detection mode.
Consistency of liver stiffness and steatosis between Hepatus and FibroScan.
Time frame: 1 to 3 years
Consistency of liver stiffness and steatosis results between Hepatus in continuous measurement mode and FibroScan in single detection mode through the respective localization methods.
The localization method of Hepatus is the real-time two-dimensional image guiding system, which is manually location in FibroScan.
Time frame: 1 to 3 years
Consistency of liver stiffness and steatosis results between Hepatus and FibroScan in single detection mode.
The localization methods include the respective localization methods in Hepatus and FibroScan, and manually locating.
Time frame: 1 to 3 years
Comparison of measurement performance in Hepatus under continuous detection mode and in FibroScan through single detection mode.
Evaluation of measurement performance includes the rate of successful detection, time taken for validated detection, stability of liver stiffness measurement and controlled attenuation parameter.
Time frame: 1 to 3 years
This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Friendship Hospital